NCT03123913View on ClinicalTrials.gov

Study of Testosterone and rHGH in FSHD

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

March 28, 2022

Study Completion Date

March 28, 2022

Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
DRUG

Testosterone Enanthate

Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.

DRUG

Somatropin

Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT03123913 - Study of Testosterone and rHGH in FSHD | Biotech Hunter | Biotech Hunter